Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine.

Authors

• Cord J Peters
• Clesson E Turner
• Gregory T Chesnut
• Veda N Giri
• Leonard G Gomella
• Craig D Shriver
• Albert Dobi

Publication/Presentation Date

6-1-2021

Abstract

UNLABELLED: INTRODUCTION The objective of our review is to summarize the 2019 Philadelphia Prostate Cancer Genetic Consensus recommendations and discuss their implications to the US Military Health System.

MATERIALS AND METHODS: Literature review.

RESULTS: Our fighting force and retired service members will significantly benefit from the Philadelphia Prostate Cancer Genetic Consensus recommendations. Moreover, the experience of the equal access US Military Health System may help advancing genetic testing for cancer at national levels.

CONCLUSIONS: Priorities recommended by the 2019 Consensus for more research on genetic predisposition to prostate cancer in racially diverse populations is a promising step. The US Military Health System has the ability of providing equal access to implement advanced germline testing for its racially diverse population.

Volume

28

Issue

3

First Page

10659

Last Page

10667

ISSN

1488-5581

Published In/Presented At

Peters, C. J., Turner, C. E., Chesnut, G. T., Giri, V. N., Gomella, L. G., Shriver, C. D., & Dobi, A. (2021). Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine. The Canadian journal of urology, 28(3), 10659–10667.

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

34129457

Department(s)

Administration and Leadership

Document Type

Article